📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-03 15:16
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Samsrita Labs Calls EGM for ₹25 Cr Related-Party Sales, ₹1 Cr CCPS & ₹1 Cr Loan
Samsrita Labs has issued a notice for an Extraordinary General Meeting (EGM) scheduled on October 26, 2026, seeking shareholder approval for key related-party transactions. The resolutions include sale of goods up to ₹25 crore to S Labs Hygiene Care Pvt Ltd, which is massive compared to Samsrita's FY26 turnover of just ₹1.81 lakhs. Additionally, the company seeks approval to invest up to ₹1 crore in CCPS of S Labs Hygiene Care and borrow up to ₹1 crore as an unsecured loan at 9% p.a. from Director Ravikanth Chopperla for working capital.
Confidence: HIGH
What changedSamsrita Labs has convened an EGM to approve significant related-party transactions covering commercial sales, equity-linked investment, and promoter/director borrowing.
Why it mattersFor a micro-cap company with virtually no operational revenue (₹1.81 lakhs in FY26) and persistent net losses (-₹8 Cr TTM), a ₹25 crore annual sales arrangement and liquidity infusion via director loan are critical shifts in scale and governance.
Related-party sales limit: Rs. 25,00,00,000/-CCPS investment limit: Rs. 1,00,00,000Unsecured loan from Director: Rs. 1,00,00,000/-Loan interest rate: 9.00% per annumFY26 Consolidated turnover: ₹1.81 Lakhs
📅 Short termE-voting cut-off is October 19, 2026, and meeting voting results will clarify if minority shareholders approve these material related-party transactions.
📈 Long termIf executed genuinely, the ₹25 crore sales cap could transform the company's dormant revenue base, but high reliance on related parties poses substantial governance and execution risks.
⚠ Risk flags
- Extremely high related-party concentration with transactions vastly exceeding existing historical revenue
- Company is currently loss-making with negligible revenue base and negative ROCE
- Unsecured borrowing from a director repayable on demand
Key Highlights
Proposed related-party sales limit of up to ₹25,00,00,000 to S Labs Hygiene Care Pvt Ltd from Oct 26, 2026 to Oct 25, 2027
Subscription to Compulsorily Convertible Preference Shares (CCPS) of S Labs Hygiene Care up to ₹1,00,00,000
Availing an unsecured loan up to ₹1,00,00,000 at 9.00% interest per annum from Non-Executive Director Ravikanth Chopperla
EGM scheduled for October 26, 2026, with the e-voting cut-off date set as October 19, 2026
👀 What to Watch
Track the outcome of the shareholder vote at the EGM on October 26, 2026, and monitor subsequent financial disclosures to see if the ₹25 crore related-party commercial activity translates into actual reported revenue.
Samsrita Labs Approves ₹26 Cr Related-Party Deals and ₹1 Cr Loan in Pet Care Pivot
Samsrita Labs' board has approved major related-party transactions with newly incorporated S Labs Hygiene Care Private Limited, an entity 80% owned by its Non-Executive Director Ravikanth Naga Pattabhi Chopperla. The company plans to invest up to ₹1.00 crore in Compulsory Convertible Preference Shares (CCPS) and enter into sale transactions of up to ₹25.00 crore in the pet care segment. Additionally, the company approved availing an unsecured working capital loan of up to ₹1.00 crore from the same director. These transactions, which are substantial relative to Samsrita's ₹28 crore market cap and negligible TTM revenue, require shareholder approval at the EGM on October 26, 2026.
Confidence: HIGH
What changedSamsrita Labs approved a ₹1 crore CCPS investment, ₹25 crore sales agreement with a newly formed pet care entity, and a ₹1 crore working capital borrowing from a common director.
Why it mattersFor a company with nearly nil revenue (₹0.02 crore in FY26) and a ₹28 crore market capitalization, these transactions represent a major pivot into pet care, but heavily rely on high-value related-party dealings.
Proposed CCPS Investment: ₹1,00,00,000Proposed Related-Party Sales: ₹25,00,00,000Unsecured Loan from Director: ₹1,00,00,000Director Stake in Target: 80%Target Incorporation Date: 10/07/2026
📅 Short termShareholder attention will focus on the upcoming EGM on October 26, 2026, to vote on these related-party transactions.
📈 Long termIf successfully executed, the pet care pivot could revitalize top-line growth, but heavy reliance on an entity controlled by an insider poses corporate governance and operational execution risks.
⚠ Risk flags
- High related-party concentration: target entity is 80% owned by a company director
- Target company is a newly incorporated shell/startup (incorporated July 10, 2026) with no prior track record
- Uncertain valuation terms for the ₹1 crore CCPS investment
Key Highlights
Proposed investment of up to ₹1,00,00,000 in CCPS of S Labs Hygiene Care Private Limited
Approval of related-party sale transactions of up to ₹25,00,00,000 with S Labs Hygiene Care
Unsecured working capital loan of up to ₹1,00,00,000 from Non-Executive Director Ravikanth Chopperla
Target entity S Labs was incorporated on 10.07.2026, with the director holding an 80% equity stake
Extra-Ordinary General Meeting (EGM) scheduled for 26.10.2026 to seek shareholder approval
👀 What to Watch
Track the outcome of the shareholder vote at the EGM on October 26, 2026, and watch for subsequent execution disclosures regarding valuation metrics and revenue materialization from the ₹25 crore sales agreement.
Samsrita Labs Reports Q1 FY27 Net Loss of ₹31.47 Lakhs on Zero Revenue
Samsrita Labs continues to struggle with zero operational revenue for the quarter ended June 30, 2026. The standalone net loss widened to ₹31.47 lakhs, compared to a loss of ₹11.87 lakhs in the preceding quarter (March 2026). Total expenses nearly doubled sequentially to ₹31.47 lakhs, primarily driven by 'Other Expenses' of ₹21.55 lakhs. With a market cap of only ₹26 crore and a history of significant losses, the company's financial health remains extremely weak.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing a widening loss and a continued lack of business activity.
Why it mattersThe company is currently a 'shell-like' entity with no revenue and a high burn rate relative to its size, posing a high risk of capital erosion for retail investors.
Revenue from Operations: ₹0.00Net Loss (Q1 FY27): ₹31.47 LakhsTotal Expenses: ₹31.47 LakhsEmployee Benefit Expenses: ₹9.80 LakhsPaid-up Equity Capital: ₹22.75 Cr
📅 Short termThe stock is likely to remain under pressure due to the lack of operational progress and widening losses.
📈 Long termThe long-term outlook is highly uncertain given the lack of a functional business model and consistent losses.
⚠ Risk flags
- Zero operational revenue
- Widening net losses
- Significant decline in promoter holding (25.44% vs 48.25% YoY)
- Micro-cap liquidity risk
Key Highlights
Revenue from operations remained at ₹0.00 for the quarter ended June 30, 2026.
Standalone net loss widened to ₹31.47 lakhs from ₹11.87 lakhs in the previous quarter.
Total expenses increased by approximately 87% quarter-on-quarter to ₹31.47 lakhs.
Employee benefit expenses rose to ₹9.80 lakhs from ₹7.83 lakhs in the preceding quarter.
The company's paid-up equity share capital stands at ₹2,274.97 lakhs.
👀 What to Watch
Investors should monitor whether the company can initiate any revenue-generating operations, as it has reported near-zero revenue for multiple quarters. The significant decline in promoter holding over the past year (from 48.25% to 25.44%) is a major red flag.
Samsrita Labs Reports Rs 18.87 Lakhs Consolidated Net Loss in Q1 FY27 on Zero Revenue
Samsrita Labs continues to report zero operational revenue for the quarter ended June 30, 2026, maintaining its pre-revenue status. On a consolidated basis, the net loss narrowed to Rs 18.87 Lakhs compared to a loss of Rs 48.16 Lakhs in the year-ago period, aided by a Rs 12.60 Lakhs profit share from associate companies. Standalone expenses increased slightly to Rs 31.47 Lakhs from Rs 27.66 Lakhs YoY, primarily due to employee benefits and administrative costs. The company's financial health remains strained with a negative TTM PAT of approximately Rs 8 Cr and a market cap of only Rs 27 Cr.
Confidence: HIGH
What changedThe filing represents the first quarter financial results for FY27, showing a continued lack of core business revenue but a reduction in consolidated losses due to associate performance.
Why it mattersFor a micro-cap company with a market cap of Rs 27 Cr, the persistent lack of revenue and reliance on associate profits indicates a lack of a functional core business model, posing high risk to shareholders.
Consolidated Net Loss: Rs 18.87 LakhsRevenue from Operations: Rs 0.00Associate Profit Share: Rs 12.60 LakhsStandalone Total Expenses: Rs 31.47 LakhsLoss vs Market Cap: ~0.07%
📅 Short termThe stock is likely to remain under pressure or stagnant given the lack of operational progress and continued losses.
📈 Long termThe long-term outlook is highly uncertain unless the company can successfully operationalize its healthcare service offerings and reverse the trend of promoter exits.
⚠ Risk flags
- Zero operational revenue
- Consistent net losses
- Significant historical promoter stake reduction
- Negative ROCE of -62.4%
Key Highlights
Revenue from operations remained at Rs 0.00 for the quarter ended June 30, 2026.
Consolidated net loss narrowed to Rs 18.87 Lakhs from Rs 48.16 Lakhs in the corresponding quarter of the previous year.
Standalone total expenses rose to Rs 31.47 Lakhs, up from Rs 27.66 Lakhs YoY.
Associate companies (Krisani Bio Sciences and Qrops Advisory) contributed a profit share of Rs 12.60 Lakhs.
Paid-up equity share capital remains at Rs 2,274.97 Lakhs with a face value of Rs 10 per share.
👀 What to Watch
Investors should monitor the company's ability to generate any operational revenue in the healthcare sector, as it has remained largely non-operational for several quarters. The significant reduction in promoter holding over the past year (from 48.25% to 25.44%) is a critical red flag to watch.
